Show Summary Details
Page of

IV Thrombolysis 3 Hours after an Acute Ischemic Stroke: The NINDS Trial 

IV Thrombolysis 3 Hours after an Acute Ischemic Stroke: The NINDS Trial
Chapter:
IV Thrombolysis 3 Hours after an Acute Ischemic Stroke: The NINDS Trial
Author(s):

Hardik P. Amin

DOI:
10.1093/med/9780199377527.003.0034
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 23 September 2019

This chapter provides a summary of a landmark study in vascular neurology. Does the use of intravenous tissue plasminogen activator to treat acute ischemic stroke improve neurologic outcomes if given within 3 hours of symptom onset? Starting with that question, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. The study established efficacy for intravenous thrombolysis treatment for ischemic stroke with improved clinical outcomes at 3 months. It provided neurologists with a proven form of treatment for acute ischemic stroke and reinforced urgency in evaluating and treating acute stroke. The chapter briefly reviews other relevant studies and information, and concludes with a relevant clinical case.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.